Knowledge base
1,260 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,260ai alignment 320internet finance 259health 207space development 171entertainment 130grand strategy 101energy 23mechanisms 18collective intelligence 14manufacturing 5robotics 5critical systems 3unknown 3teleological economics 1
Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, a
GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
The joint advisory from OMA, ASN, ACLM, and The Obesity Society explicitly identifies food insecurity and nutrition insecurity as barriers to equitable obesity management with GLP-1s. The screening checklist includes food insecurity, nutrition insecurity, and housing/transportation challenges. The a
GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
GLP-1 receptor agonists suppress appetite as their primary mechanism, reducing caloric intake by 20-30%. This creates systematic micronutrient deficiency risk across iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C. The joint advisory from four major obesity/nutrition organiza
GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics a
GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk
GLP-1 receptor agonists reduce HF hospitalization and mortality by 40%+ in obese HFpEF patients (STEP-HFpEF). However, this same population faces a hidden paradox: 32.8% of hospitalized HFpEF patients are obese, and among these obese patients (average BMI 33 kg/m²), many are malnourished with sarcop
GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macr
Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
Never-skilling presents a unique detection challenge that distinguishes it from deskilling. When a physician loses existing skills through disuse (deskilling), the degradation is detectable through comparison to their previous baseline performance. But when a trainee never acquires foundational comp
Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose
A Danish cohort study of an online weight-loss program combining behavioral support with individualized semaglutide dosing achieved 16.7% baseline weight loss over 64 weeks—matching STEP clinical trial outcomes of 15-17%—while using approximately half the typical drug dose. This finding suggests beh
Double coverage compression occurs when Medicaid work requirements contract coverage below 138 percent FPL while APTC expiry eliminates subsidies for 138-400 percent FPL simultaneously
OBBBA creates what can be termed 'double coverage compression'—the simultaneous contraction of both major coverage pathways for low-income populations. Medicaid work requirements affect populations below 138% FPL (the Medicaid expansion threshold), while APTC (Advance Premium Tax Credits) expired in
GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straight
GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained
GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking dive
GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked
OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026
OBBBA requires all states to implement Medicaid work requirements (80+ hours/month for ages 19-64) by December 31, 2026, with CMS issuing implementation guidance by June 1, 2026. This creates a structural conflict with value-based care economics. VBC models require 12-36 month enrollment stability t
OBBBA SNAP cuts represent the largest food assistance reduction in US history at $186 billion through 2034, removing continuous nutritional support from 2.4 million people despite evidence that SNAP participation reduces healthcare costs by 25 percent
OBBBA's SNAP provisions cut $186 billion through 2034 through Thrifty Food Plan formula adjustments and work requirement expansions, making this the largest food assistance reduction in US history. The cuts are projected to remove 2.4 million people from SNAP by 2034, with more than 1 million older
Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
The SCORE study tracked 9,321 individuals with ASCVD and overweight/obesity (without diabetes) who initiated semaglutide 2.4mg, matched to 18,642 controls over mean 200-day follow-up. Semaglutide was associated with HR 0.43 for revised 3-point MACE and HR 0.55 for revised 5-point MACE (both p<0.001)
Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
The STEER study (n=10,625 matched patients with overweight/obesity and ASCVD without diabetes) found semaglutide associated with 29% lower revised 3-point MACE versus tirzepatide (HR 0.71), 22% lower revised 5-point MACE, and in per-protocol analysis 43-57% reductions in favor of semaglutide. This f
Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysi
OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden
OBBBA shifts SNAP costs to states, with Pew analysis projecting states' collective SNAP costs will rise $15 billion annually once phased in. This creates a fiscal cascade mechanism: states facing dual cost pressure from new SNAP state share requirements and new Medicaid administrative requirements (
Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
The JACC 2026 Cardiovascular Statistics report documents that long-term mortality gains are 'slowing or reversing' across coronary heart disease, acute MI, heart failure, peripheral artery disease, and stroke. Heart failure mortality specifically has been increasing since 2012 and is now 3% higher t
US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
The JACC inaugural Cardiovascular Statistics report documents that hypertension-related cardiovascular deaths nearly doubled from 23 to 43 per 100,000 population between 2000 and 2019, while treatment and control rates have remained stagnant for 15 years. Nearly 1 in 2 US adults meet current hyperte
Cipla's dual role as generic semaglutide entrant AND Lilly's branded tirzepatide partner exemplifies the portfolio hedge strategy for pharmaceutical companies navigating market bifurcation
Cipla, India's major generic manufacturer, is simultaneously positioned as (1) the likely dominant generic semaglutide entrant following March 2026 patent expiry and (2) Eli Lilly's exclusive distribution partner for branded tirzepatide (Yurpeak) targeting smaller Indian cities. This dual positionin
Clinical AI that reinforces physician plans amplifies existing demographic biases at population scale because both physician behavior and LLM training data encode historical inequities
The Nature Medicine finding that LLMs exhibit systematic sociodemographic bias across all model types creates a specific safety concern for clinical AI systems designed to 'reinforce physician plans' rather than replace physician judgment. Research on physician behavior already documents demographic
Clinical AI errors are 76 percent omissions not commissions inverting the hallucination safety model
The NOHARM study evaluated 31 large language models against 100 real primary care consultation cases from Stanford Health Care with 12,747 expert annotations. Across all models, harms of omission accounted for 76.6% (95% CI 76.4-76.8%) of all severe errors, while commissions represented only 23.4%.
CVD mortality stagnation after 2010 affects all income levels including the wealthiest counties indicating structural system failure not poverty correlation
The pervasive nature of CVD mortality stagnation across all income deciles—including the wealthiest counties—demonstrates this is a structural, system-wide phenomenon rather than a poverty-driven outcome. While county-level median household income was associated with the absolute level of CVD mortal
Page 3 of 9